{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:43:56Z","timestamp":1787028236240,"version":"build-2736575974"},"reference-count":51,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T00:00:00Z","timestamp":1684713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100018712","name":"Iuliu Hatieganu University of Medicine and Pharmacy","doi-asserted-by":"publisher","award":["5200\/79\/2017"],"award-info":[{"award-number":["5200\/79\/2017"]}],"id":[{"id":"10.13039\/501100018712","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Genes"],"abstract":"<jats:p>Psoriasis is a systemic inflammatory disease that associates with multiple comorbidities. It involves complex interactions between environmental factors and polygenic predisposition. The IL-17 family is one of the main actors in the pathogenesis of psoriasis. Secondary nonresponse is common, especially during the long-term use of TNF-\u03b1 inhibitors, but it is not uncommon even for newer biologics, such as IL-17 inhibitors. Identification of clinically useful biomarkers of treatment efficacy and safety would enable optimal treatment selection, improve patient quality of life and outcome, and reduce healthcare costs. To our knowledge, this is the first study to evaluate the relationship between genetic polymorphism of IL-17F (rs763780) and IL-17RA (rs4819554) and response to biological treatment and other clinical data in bio-naive and secondary non-responders psoriasis patients in Romania and Southeastern Europe. We performed a prospective, longitudinal, analytical cohort study of 81 patients diagnosed with moderate-to-severe chronic plaque psoriasis who received biological treatments for the first time. Of the 79 patients treated with TNF-\u03b1 inhibitors, 44 experienced secondary nonresponse. All patients were genotyped for the two SNPs in IL-17F and IL-17RA genes. The rs763780 polymorphism in the IL-17F gene could be an attractive candidate biomarker for predicting which patients will respond to anti-TNF-\u03b1 therapies. Another emergent association of rs4819554 in IL-17RA with the risk of nail psoriasis and a higher BMI in moderate-to-severe plaque psoriasis patients is described.<\/jats:p>","DOI":"10.3390\/genes14051123","type":"journal-article","created":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T01:36:48Z","timestamp":1684805808000},"page":"1123","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Association between IL-17F, IL-17RA Gene Polymorphisms and Response to Biological Drugs in Psoriasis and Beyond"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-8817-3914","authenticated-orcid":false,"given":"Alexandra Dana","family":"Pu\u0219ca\u0219","sequence":"first","affiliation":[{"name":"Department of Physiology, University of Medicine and Pharmacy Iuliu Hatieganu, 400347 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iulia Ioana","family":"Morar","sequence":"additional","affiliation":[{"name":"Department of Pathophysiology, University of Medicine and Pharmacy Iuliu Hatieganu, 400347 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4549-3526","authenticated-orcid":false,"given":"\u0218tefan Cristian","family":"Vesa","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Toxicology, and Clinical Pharmacology, University of Medicine and Pharmacy Iuliu Hatieganu, 400347 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreea","family":"C\u0103tan\u0103","sequence":"additional","affiliation":[{"name":"Department of Genetics, University of Medicine and Pharmacy Iuliu Hatieganu, 400347 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristian","family":"Pu\u0219ca\u0219","sequence":"additional","affiliation":[{"name":"Vadaskert Child and Youth Psychiatry Hospital, 1021 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxana Flavia","family":"Ilie\u0219","sequence":"additional","affiliation":[{"name":"Department of Genetics, University of Medicine and Pharmacy Iuliu Hatieganu, 400347 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Remus-Ioan","family":"Orasan","sequence":"additional","affiliation":[{"name":"Department of Physiology, University of Medicine and Pharmacy Iuliu Hatieganu, 400347 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,5,22]]},"reference":[{"key":"ref_1","unstructured":"Michalek, I.M., Loring, B., and John, S.M. (2023, April 29). Global Report on Psoriasis. World Health Organization Home Page. Available online: https:\/\/www.who.int\/publications\/i\/item\/9789241565189."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1055\/s-0042-1743259","article-title":"Psoriasis: An Immunogenetic Perspective","volume":"9","author":"Kocaaga","year":"2022","journal-title":"Glob. Med. Genet."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Rendon, A., and Sch\u00e4kel, K. (2019). Psoriasis Pathogenesis and Treatment. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20061475"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Vi\u010di\u0107, M., Ka\u0161telan, M., Brajac, I., Soto\u0161ek, V., and Massari, L.P. (2021). Current Concepts of Psoriasis Immunopathogenesis. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222111574"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/jdv.13854","article-title":"A Systematic Review of Worldwide Epidemiology of Psoriasis","volume":"31","author":"Michalek","year":"2017","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.3389\/fimmu.2019.01764","article-title":"Adaptive and Innate Immunity in Psoriasis and Other Inflammatory Disorders","volume":"10","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/bs.acc.2020.04.004","article-title":"Cytokines in Psoriasis","volume":"100","author":"Reiche","year":"2021","journal-title":"Adv. Clin. Chem."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1007\/s00011-021-01514-6","article-title":"Association between IL-17A, IL-17F and IL-17RA Gene Polymorphisms and Susceptibility to Psoriasis and Psoriatic Arthritis: A Meta-Analysis","volume":"70","year":"2021","journal-title":"Inflamm. Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.jdermsci.2015.06.011","article-title":"Association between Single Nucleotide Polymorphisms IL17RA Rs4819554 and IL17E Rs79877597 and Psoriasis in a Spanish Cohort","volume":"80","author":"Batalla","year":"2015","journal-title":"J. Dermatol. Sci."},{"key":"ref_11","first-page":"251","article-title":"Targeting of Interleukin-17 in the Treatment of Psoriasis","volume":"7","author":"Zachariae","year":"2014","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3109\/09546634.2013.879093","article-title":"The Role of IL-17 in Psoriasis","volume":"26","author":"Malakouti","year":"2015","journal-title":"J. Dermatol. Treat."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.jaci.2004.10.019","article-title":"IL-17 Cytokine Family","volume":"114","author":"Kawaguchi","year":"2004","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.2217\/pgs.15.107","article-title":"The Polymorphism Rs763780 in the IL-17F Gene Is Associated with Response to Biological Drugs in Patients with Psoriasis","volume":"16","author":"Cabaleiro","year":"2015","journal-title":"Pharmacogenomics"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00281-015-0539-8","article-title":"Update on Psoriasis Immunopathogenesis and Targeted Immunotherapy","volume":"38","author":"Mahil","year":"2016","journal-title":"Semin. Immunopathol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0001-7310(14)70014-6","article-title":"Pathogenic Role of IL-17 in Psoriasis and Psoriatic Arthritis","volume":"105","author":"Chiricozzi","year":"2014","journal-title":"Actas. Dermosifiliogr."},{"key":"ref_17","first-page":"76","article-title":"IL17RA Gene Variants and Anti-TNF Response among Psoriasis Patients","volume":"18","author":"Batalla","year":"2018","journal-title":"Pharm. J."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"937490","DOI":"10.3389\/fphar.2022.937490","article-title":"The Inflammatory Factor SNP May Serve as a Promising Biomarker for Acitretin to Alleviate Secondary Failure of Response to TNF-a Monoclonal Antibodies in Psoriasis","volume":"13","author":"Lin","year":"2022","journal-title":"Front. Pharmacol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"170","DOI":"10.7861\/clinmed.2021-0257","article-title":"Psoriasis: A Brief Overview","volume":"21","author":"Raharja","year":"2021","journal-title":"Clin. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1080\/14712598.2022.2113872","article-title":"New Frontiers in Personalized Medicine in Psoriasis","volume":"22","author":"Camela","year":"2022","journal-title":"Expert. Opin. Biol. Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jaci.2012.04.024","article-title":"IL-17A Is Essential for Cell Activation and Inflammatory Gene Circuits in Subjects with Psoriasis","volume":"130","author":"Krueger","year":"2012","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"102398","DOI":"10.1016\/j.autrev.2019.102398","article-title":"Failure of Anti-TNF Treatment in Patients with Rheumatoid Arthritis: The Pros and Cons of the Early Use of Alternative Biological Agents","volume":"18","author":"Kedves","year":"2019","journal-title":"Autoimmun. Rev."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1111\/bjd.16252","article-title":"Clinical Experience of Secukinumab in the Treatment of Erythrodermic Psoriasis: A Case Series","volume":"178","author":"Weng","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1136\/annrheumdis-2021-220202","article-title":"Primary and Secondary Non-Response: In Need of Operational Definitions in Observational Studies","volume":"80","author":"Keystone","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Kamiya, K., Kishimoto, M., Sugai, J., Komine, M., and Ohtsuki, M. (2019). Risk Factors for the Development of Psoriasis. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20184347"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"150","DOI":"10.25259\/IJDVL_1401_20","article-title":"Association between Interleukin-17F Rs763780 Polymorphism and Psoriasis Risk: A Meta-Analysis","volume":"88","author":"Xiang","year":"2022","journal-title":"Indian J. Dermatol. Venereol. Leprol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"18921","DOI":"10.1038\/s41598-019-55062-5","article-title":"The IL17F His161Arg Polymorphism, a Potential Risk Locus for Psoriasis, Increases Serum Levels of Interleukin-17F in an Asian Population","volume":"9","author":"Choi","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/cei.12888","article-title":"A Preliminary Study of New Single Polymorphisms in the T Helper Type 17 Pathway for Psoriasis in the Korean Population","volume":"187","author":"Kim","year":"2017","journal-title":"Clin. Exp. Immunol."},{"key":"ref_30","first-page":"39","article-title":"Association of Genetic Variants of the Interleukin-17F Rs763780 and Its Circulating Level in Psoriasis Patients in Egypt","volume":"27","author":"Fouad","year":"2020","journal-title":"Egypt J. Immunol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"422","DOI":"10.4103\/ijmr.IJMR_1859_16","article-title":"Association of Genetic Polymorphism of Interleukin-17A & Interleukin-17F with Susceptibility of Psoriasis","volume":"148","author":"Kaur","year":"2018","journal-title":"Indian J. Med. Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s00403-019-02011-x","article-title":"A Potential Association between Psoriasin to Rs4819554 of IL-17RA Gene Polymorphism in Psoriasis Egyptian Patients","volume":"312","author":"Sabry","year":"2020","journal-title":"Arch. Dermatol. Res."},{"key":"ref_33","first-page":"297","article-title":"Gene Polymorphisms That Can Predict Response to Anti-TNF Therapy in Patients with Psoriasis and Related Autoimmune Diseases","volume":"13","author":"Cabaleiro","year":"2013","journal-title":"Pharm. J."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/bjd.21677","article-title":"Biomarkers of Systemic Treatment Response in People with Psoriasis: A Scoping Review","volume":"187","author":"Corbett","year":"2022","journal-title":"Br. J. Dermatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00403-010-1080-1","article-title":"Definition of treatment goals for moderate to severe psoriasis: A European consensus","volume":"303","author":"Mrowietz","year":"2011","journal-title":"Arch Dermatol Res."},{"key":"ref_36","first-page":"12928","article-title":"Association between IL-17F Rs763780 Polymorphism and Susceptibility of Asthma: A Meta-Analysis","volume":"8","author":"Ke","year":"2015","journal-title":"Int. J. Clin. Exp. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.jaci.2005.12.1346","article-title":"IL-17F Sequence Variant (His161Arg) Is Associated with Protection against Asthma and Antagonizes Wild-Type IL-17F Activity","volume":"117","author":"Kawaguchi","year":"2006","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s10875-007-9125-8","article-title":"The Influence of Polymorphisms of Interleukin-17A and Interleukin-17F Genes on the Susceptibility to Ulcerative Colitis","volume":"28","author":"Arisawa","year":"2008","journal-title":"J. Clin. Immunol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1159\/000448090","article-title":"IL17A and IL17F Gene Polymorphism Association with Psoriasis Risk and Response to Treatment in a Polish Population","volume":"232","author":"Bialecka","year":"2017","journal-title":"Dermatology"},{"key":"ref_40","first-page":"875","article-title":"Psoriasis: Association of Interleukin-17 Gene Polymorphisms with Severity and Response to Treatment","volume":"18","author":"Roman","year":"2019","journal-title":"Exp. Ther. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"780","DOI":"10.5114\/ada.2020.95383","article-title":"Evaluation of the Relationship of IL-17A and IL-17F Gene Polymorphisms with the Response to Treatment in Psoriatic Patients Using Biological Drugs: A Case-Control Study in Patients in Eastern Turkey","volume":"38","author":"Ozkol","year":"2021","journal-title":"Postep. Dermatol. Alergol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/BF03256427","article-title":"Pharmacogenetic Analysis of TNF, TNFRSF1A, and TNFRSF1B Gene Polymorphisms and Prediction of Response to Anti-TNF Therapy in Psoriasis Patients in the Greek Population","volume":"16","author":"Vasilopoulos","year":"2012","journal-title":"Mol. Diagn. Ther."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Chiricozzi, A., Nograles, K.E., Johnson-Huang, L.M., Fuentes-Duculan, J., Cardinale, I., Bonifacio, K.M., Gulati, N., Mitsui, H., Guttman-Yassky, E., and Suarez-Farinas, M. (2014). IL-17 Induces an Expanded Range of Downstream Genes in Reconstituted Human Epidermis Model. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0090284"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00005-014-0319-5","article-title":"IL-17A, IL-17F and IL-23R Gene Polymorphisms in Polish Patients with Rheumatoid Arthritis","volume":"63","author":"Malak","year":"2015","journal-title":"Arch. Immunol. Ther. Exp."},{"key":"ref_45","first-page":"3125922","article-title":"Polymorphisms within Genes Coding for IL-17A and F and Their Receptor as Clinical Hallmarks in Ankylosing Spondylitis","volume":"2021","author":"Kolossa","year":"2021","journal-title":"Mediat. Inflamm."},{"key":"ref_46","first-page":"1","article-title":"Efficacy of Biologics Targeting Tumour Necrosis Factor-Alpha, Interleukin-17-12\/23,-23 and Small Molecules Targeting Jak and Pde4 in the Treatment of Nail Psoriasis: A Network Meta-Analysis","volume":"100","author":"Gede","year":"2020","journal-title":"Acta Derm. Venereol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"adv00787","DOI":"10.2340\/actadv.v102.2269","article-title":"Sustained Resolution of Nail Psoriasis Through 5 Years with Ixekizumab: A Post-Hoc Analysis from UNCOVER-3","volume":"102","author":"Egeberg","year":"2022","journal-title":"Acta Derm. Venereol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.jaad.2005.11.1079","article-title":"Psoriasis Is Associated with Lipid Abnormalities at the Onset of Skin Disease","volume":"54","author":"Mallbris","year":"2006","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1159\/000455840","article-title":"Psoriasis and Obesity","volume":"232","author":"Jensen","year":"2017","journal-title":"Dermatology"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"699848","DOI":"10.3389\/fimmu.2021.699848","article-title":"Depression and Obesity in Patients With Psoriasis and Psoriatic Arthritis: Is IL-17-Mediated Immune Dysregulation the Connecting Link?","volume":"12","author":"Zafiriou","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_51","unstructured":"Bolognia, J.L., Schaffer, J.V., and Cerroni, L. (2018). Fourth Edition Dermatology, Elsevier."}],"container-title":["Genes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4425\/14\/5\/1123\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:40:08Z","timestamp":1760125208000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4425\/14\/5\/1123"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,22]]},"references-count":51,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,5]]}},"alternative-id":["genes14051123"],"URL":"https:\/\/doi.org\/10.3390\/genes14051123","relation":{},"ISSN":["2073-4425"],"issn-type":[{"value":"2073-4425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,22]]}}}